News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sophiris Bio Inc. (SPHS) Reports Second Quarter Financial Results And Key Operational And Financial Highlights


8/8/2014 9:13:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing PRX302 for the treatment of the symptoms of benign prostatic hyperplasia (BPH, enlarged prostate) and for the treatment of localized prostate cancer, today announced financial results and recent key operational and financial highlights for the three and six months ended June 30, 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES